| Title |
Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency
|
|---|---|
| Published in |
Biologics: Targets & Therapy, March 2010
|
| DOI | 10.2147/btt.s3014 |
| Pubmed ID | |
| Authors |
Sabine Kroiss, Manuela Albisetti |
| Abstract |
Protein C is one of the major inhibitors of the coagulation system that downregulate thrombin generation. Severe congenital protein C deficiency leads to a hypercoagulability state that usually presents at birth with purpura fulminans and/or severe venous and arterial thrombosis. Recurrent thrombotic events are commonly seen. From the 1990's, several virus-inactivated human protein C concentrates have been developed. These concentrates currently constitute the therapy of choice for the treatment and prevention of clinical manifestations of severe congenital protein C deficiency. This review summarizes the available information on the use of human protein C concentrates in patients with severe congenital protein C deficiency. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 5% |
| Unknown | 21 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 18% |
| Student > Bachelor | 3 | 14% |
| Other | 3 | 14% |
| Student > Ph. D. Student | 2 | 9% |
| Professor > Associate Professor | 2 | 9% |
| Other | 5 | 23% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 55% |
| Agricultural and Biological Sciences | 2 | 9% |
| Immunology and Microbiology | 1 | 5% |
| Computer Science | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2023.
All research outputs
#8,713,411
of 25,806,080 outputs
Outputs from Biologics: Targets & Therapy
#109
of 286 outputs
Outputs of similar age
#39,043
of 104,001 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 5 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 104,001 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.